Peptonic Medical and Orion sign VagiVital® distribution agreement for Finland
Stockholm den 29th June 2018 - Peptonic Medical AB (publ) (’Peptonic’) or (’Company’) today announced that it has entered a distribution agreement for its hormone-free self-care product VagiVital® with Orion Corporation (‘Orion’) concerning Finland. Orion plans to launch the Product under its own brand name later this year.
- We are proud to have developed and extended the collaboration with Orion to also include commercialisation of our hormone-free self-care product for the treatment of vaginal dryness, says Johan Inborr, CEO of Peptonic Medical. Orion has a strong position in the self-care market in Finland and it has high ambitions for the Product.
The agreement is exclusive to Orion.
Peptonic received the CE mark for VagiVital® in May, which means it can be marketed and distributed in the EU.
For more information, please contact;
Johan Inborr, CEO
Mobile: +46 708 853 893
This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 29 June 2018.
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's adjusted net sales in 2017 amounted to EUR 1,034 million and the company had about 3,200 employees. Orion's A and B shares are listed on Nasdaq Helsinki.
For more information: www.orion.fi/en
About Peptonic Medical
Peptonic Medical is an innovative Swedish development company. Our vision is to offer safe and effective treatments for women suffering from vaginal atrophy during menopause and after.
VagiVital® is a trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy.
The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.
In July 2014, Peptonic Medical was listed on the AktieTorget stock exchange (www.aktietorget.se, ticker: PMED) in Stockholm.
For more information: www.peptonicmedical.com
VagiVital® is a hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects.
Peptonic Medical plans to launch VagiVital® as a non-prescription self-care product in 2018.